Full Press Release Details
Immutep Secures Third United States Patent for Eftilagimod Alpha
in Combination with a PD-1 Pathway Inhibitor
SYDNEY, AUSTRALIA 27 June 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology
company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announced the grant of a new patent (number 11,684,654) entitled Combined Preparations for the Treatment of Cancer
or Infection by the United States Patent Office.
This United States patent was filed as a second divisional application and follows the grant of
the United States parent patent and first divisional patent announced in December 2020 and March 2021, respectively.
The claims of the new patent build
on the protection provided by the two previously granted patents, and are directed to methods of treating cancer by administering Immutep s lead active immunotherapy candidate eftilagimod alpha ( efti ) and a PD-1 pathway inhibitor, specifically BMS-936559, durvalumab, atezolizumab or avelumab. The expiry date of the patent is 15 November 2036 (including 312 days of patent
We continue to build our patent estate around lead candidate efti, which is a unique biomolecule and shows great promise in being
able to ultimately help diverse sets of cancer patients, including those with more complex needs. Here we add another key US patent which is closely aligned with our clinical development pipeline. These key patents support ongoing investment and
allow us to confidently push forward across all of our business functions, including clinical, manufacturing, and business development, said Marc Voigt, CEO of Immutep.
A continuation application and a further divisional application have been filed to pursue other embodiments of the invention.
About Eftilagimod Alpha (Efti)
proprietary soluble LAG-3 clinical stage candidate that is a first-in-class antigen presenting cell (APC) activator that
stimulates both innate and adaptive immunity for the treatment of cancer. Efti binds to and activates antigen-presenting cells via MHC II molecules leading to expansion and proliferation of CD8+
(cytotoxic) T cells, CD4+ (helper) T cells, dendritic cells, NK cells, and monocytes. It also upregulates the expression of key biological molecules like
IFN- and CXCL10 that further boost the immune system s ability to fight cancer.
Efti is under evaluation for a variety of solid tumours including non-small cell lung cancer (NSCLC), head and neck
squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its favourable safety profile enables various combinations, including with anti-PD-[L]1 immunotherapy
and/or chemotherapy.
Efti has received Fast Track Designation in 1st line HNSCC and in 1st line NSCLC from the United States Food and Drug Administration
Immutep is a clinical-stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune
disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and our diversified product portfolio
harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to market for patients in need and to maximise value for shareholders. For more
information, please visit www.immutep.com.
Australian Investors/Media:
Catherine Strong, Citadel-MAGNUS
U.S. Investors/Media:
Chris Basta, VP, Investor Relations and Corporate Communications
+1 (631) 318 4000; chris.basta@immutep.com
announcement was authorised for release by the CEO of Immutep Limited.
Immutep Limited, Level 33, Australia Square, 264 George
Street, Sydney NSW 2000, Australia